Rising demand for IVF in China will strain already-crowded state-run hospitals but create opportunities for overseas health centers.» Read More
Michael Yee, BioTech Analyst, RBC Capital Markets, on why shares of Gilead are up 12 percent so far this year.
Pfizer's proposed acquisition of Allergan will be one of the biggest tax inversions yet.
Activist investor Bill Ackman's hedge fund has increased its investment in Valeant, and signaled it may play a greater role in its strategy.
John Burke, CEO, Burke Financial Strategies, explains why he remains bullish on Pfizer shares.
Shares of KaloBios jumped after Martin Skhreli took a 70 percent stake in the name.
Pershing Square Capital Management revealed Monday that it had boosted its stake in Valeant Pharmaceuticals.
Pfizer is buying Allergan for about $160 billion. CNBC's Meg Tirrell reports on the reaction by lobbyists and analysts.
CNBC's Eamon Javers reports on the White House and Democratic Presidential Candidate Hillary Clinton's reaction to the Pfizer-Allergan deal.
CNBC's Meg Tirrell looks at the details of Pfizer's $160 billion acquisition of Allergan.
Barbara Ryan, Clermont Partners, weighs in on terms of the deal which is expected to close in the second half of 2016.
CNBC's Meg Tirrell reports details of the merger which will create the world's largest pharma company to be headquartered in Dublin, Ireland.
CNBC's Meg Tirrell breaks down terms of the deal which would create the world's largest pharma company.
Pfizer's record deal with Allergan will allow the New York-based drug giant to relocate to Ireland to cut its U.S. tax burden.
Vamil Divan, Credit Suisse analyst, discusses benefits of the mega deal, including tax inversion and freeing up funds for research and development.
Pfizer secured formal board approval on Sunday for its acquisition of Botox maker Allergan, according to people familiar with the matter.
The "Fast Money" traders give their final trades of the day.
CNBC's Meg Tirrell reports on two drugs approaching the FDA that could contribute to treating the rare disease of Duchenne Muscular Dystrophy.
Former Sanofi CEO Chris Viehbacher discusses how his new drug company plans to succeed in the early phases of drug development.
AquaBounty has received approval from the FDA to sell its AquAdvantage salmon in the US, but critics have denounced the 'frankenfish.'
Pfizer and Allergan are in the final stages of discussions to merge, sources told CNBC on Thursday.
Get the best of CNBC in your inbox